- Home
- ASRT vs XFOR Comparison
ASRT vs XFOR Comparison
Compare ASRT & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASRT | XFOR |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.0M | 407.5M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASRT | XFOR |
|---|---|---|
| Price | $19.39 | $4.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $35.00 | $25.20 |
| AVG Volume (30 Days) | 103.8K | ★ 531.1K |
| Earning Date | 03-16-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $118,713,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.87 | $80.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $0.17 |
| 52 Week High | $20.45 | $6.63 |
Technical Indicators
Market Signals| Indicator | ASRT | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 84.05 | 52.84 |
| Support Level | $0.69 | $3.01 |
| Resistance Level | N/A | $4.34 |
| Average True Range (ATR) | 1.10 | 0.36 |
| MACD | 0.75 | 0.01 |
| Stochastic Oscillator | 85.41 | 40.00 |
Price Performance
Historical ComparisonAbout ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.